子宫肌瘤症状性治疗后的长期健康相关生活质量与症状严重程度:子宫切除术、子宫肌瘤剔除术与子宫动脉栓塞术的比较
COMPARE-UF多机构前瞻性观察队列纳入1384例31~45岁接受腹部或腹腔镜子宫肌瘤剔除术、腹部或腹腔镜子宫切除术或子宫动脉栓塞术的患者,比较基线至术后1、2、3年健康相关生活质量与症状严重程度变化;所有术式1年时均显著改善,但保留子宫的术式至第3年改善程度逐渐下降。
要点
- 所有术式术后1年健康相关生活质量与症状严重程度均显著改善,以腹腔镜子宫切除术改善幅度最大。
- 腹部肌瘤剔除术、腹腔镜肌瘤剔除术和子宫动脉栓塞术的改善在术后第2、3年仍持续,但较第1年呈下降趋势。
- 基线时子宫切除术和子宫动脉栓塞术组生活质量最低、症状最重,症状持续时间最长(均值6.3年)。
核心结论
- 所有治疗方式均与术后1年健康相关生活质量和症状严重程度的显著改善相关。
- 腹部子宫肌瘤剔除术、腹腔镜子宫肌瘤剔除术和子宫动脉栓塞术至术后第3年症状改善和生活质量呈逐渐下降趋势。
研究设计与样本
- COMPARE-UF注册研究为多机构前瞻性观察队列研究,纳入接受子宫肌瘤治疗的女性。
- 本分析纳入1384例31~45岁女性,包括腹部子宫肌瘤剔除术237例、腹腔镜子宫肌瘤剔除术272例、腹部子宫切除术177例、腹腔镜子宫切除术522例、子宫动脉栓塞术176例。
- 入组时及治疗后1、2、3年通过问卷收集人口学、肌瘤病史和症状。
- 采用子宫肌瘤症状与生活质量(UFS-QoL)问卷评估症状严重程度和健康相关生活质量评分。
- 使用倾向评分模型推导重叠权重,并以重复测量模型比较入组后总分。
主要发现
- 基线时,子宫切除术和子宫动脉栓塞术组健康相关生活质量评分最低、症状严重程度评分最高,与腹部子宫肌瘤剔除术或腹腔镜子宫肌瘤剔除术组相比P<.001。
- 子宫切除术和子宫动脉栓塞术组肌瘤症状持续时间最长,均值为6.3年(标准差6.7;P<.001)。
- 最常见肌瘤症状为月经过多(75.3%)、占位症状(74.2%)和腹胀(73.2%);超过一半(54.9%)报告贫血,9.4%报告有输血史。
- 所有方式从基线至1年健康相关生活质量和症状严重程度总分均显著改善,腹腔镜子宫切除术组改善最大(UFS-QoL:变化值=+49.2;症状严重程度:变化值=-51.3)。
- 腹部子宫肌瘤剔除术、腹腔镜子宫肌瘤剔除术和子宫动脉栓塞术1年时健康相关生活质量亦显著改善(变化值分别为+43.9、+32.9、+40.7),症状严重程度改善(变化值分别为-41.4、-31.5、-38.5)。
局限性
- 该生活质量工具未确定特定的最小临床重要差值,基于既往研究将10分差异视为合理估计,分析计划时指导委员会同意使用该差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Few studies have directly compared different surgical procedures for uterine fibroids with respect to long-term health-related quality of life outcomes and symptom improvement. OBJECTIVE: We examined differences in change from baseline to 1-, 2-, and 3-year follow-up in health-related quality of life and symptom severity among patients who underwent abdominal myomectomy, laparoscopic or robotic myomectomy, abdominal hysterectomy, laparoscopic or robotic hysterectomy, or uterine artery embolization. STUDY DESIGN: The COMPARE-UF registry is a multiinstitutional prospective observational cohort study of women undergoing treatment for uterine fibroids. A subset of 1384 women aged 31 to 45 years who underwent either abdominal myomectomy (n=237), laparoscopic myomectomy (n=272), abdominal hysterectomy (n=177), laparoscopic hysterectomy (n=522), or uterine artery embolization (n=176) were included in this analysis. We obtained demographics, fibroid history, and symptoms by questionnaires at enrollment and at 1, 2, and 3 years posttreatment. We used the UFS-QoL (Uterine Fibroid Symptom and Quality of Life) questionnaire to ascertain symptom severity and health-related quality of life scores among participants. To account for potential baseline differences across treatment groups, a propensity score model was used to derive overlap weights and compare total health-related quality of life and symptom severity scores after enrollment with a repeated measures model. For this health-related quality of life tool, a specific minimal clinically important difference has not been determined, but on the basis of previous research, a difference of 10 points was considered as a reasonable estimate. Use of this difference was agreed upon by the Steering Committee at the time when the analysis was planned. RESULTS: At baseline, women undergoing hysterectomy and uterine artery embolization reported the lowest health-related quality of life scores and highest symptom severity scores compared with those undergoing abdominal myomectomy or laparoscopic myomectomy (P<.001). Those undergoing hysterectomy and uterine artery embolization reported the longest duration of fibroid symptoms with a mean of 6.3 years (standard deviation, 6.7; P<.001). The most common fibroid symptoms were menorrhagia (75.3%), bulk symptoms (74.2%), and bloating (73.2%). More than half (54.9%) of participants reported anemia, and 9.4% women reported a history of blood transfusion. Across all modalities, total health-related quality of life and symptom severity score markedly improved from baseline to 1-year with the largest improvement in the laparoscopic hysterectomy group (Uterine Fibroids Symptom and Quality of Life: delta= [+] 49.2; symptom severity: delta= [-] 51.3). Those undergoing abdominal myomectomy, laparoscopic myomectomy, and uterine artery embolization also demonstrated significant improvement in health-related quality of life (delta= [+]43.9, [+]32.9, [+]40.7, respectively) and symptom severity (delta= [-]41.4, [-] 31.5, [-] 38.5, respectively) at 1 year, and the improvement persisted from baseline for uterine-sparing procedures during second (Uterine Fibroids Symptom and Quality of Life: delta= [+]40.7, [+]37.4, [+]39.3 SS: delta= [-] 38.5, [-] 32.0, [-] 37.7 and third year (Uterine Fibroids Symptom and Quality of Life: delta= [+] 40.9, [+]39.9, [+]41.1 and SS: delta= [-] 33.9, [-]36.5, [-] 33.0, respectively), posttreatment intervals, however with a trend toward decline in degree of improvement from years 1 and 2. Differences from baseline were greatest for hysterectomy; however, this may reflect the relative importance of bleeding in the Uterine Fibroids Symptom and Quality of Life, rather than clinically meaningful symptom recurrence among women undergoing uterus-sparing treatments. CONCLUSION: All treatment modalities were associated with significant improvements in health-related quality of life and symptom severity reduction 1-year posttreatment. However, abdominal myomectomy, laparoscopic myomectomy and uterine artery embolization indicated a gradual decline in symptom improvement and health-related quality of life by third year after the procedure.
引用
- Anchan RM, Spies JB, Zhang S, et al. Long-term health-related quality of life and symptom severity following hysterectomy, myomectomy, or uterine artery embolization for the treatment of symptomatic uterine fibroids. Am J Obstet Gynecol. 2023. PMID: 37244458. doi:10.1016/j.ajog.2023.05.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。